Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: An innovative solution has been recently proposed for the treatment of heart failure with preserved ejection fraction (HFpEF), using a centrifugal mechanical circulatory support (MCS) device. We sought firstly to assess the hemocompatibility of the proposed device. HFpEF treatment requires the blood pump to operate at low blood flow rate (0.05-0.5 L/min). Given high blood trauma expected in these conditions, we sought secondly to investigate design improvements in order to reduce this risk.
Method: Computational fluid dynamics was used to analyze the blood fluid filled within the centrifugal pump and to estimate the blood trauma due to its operation. This assessment is based on the computation of integrated quantities such as the hemolysis index and the turbulent dissipation energy.
Results: The hemolysis index associated with the present device is comparable to the figures from HVAD. With the proposed pump, for instance, an index of 0.0036 is obtained at 1 L/min and 3000 rpm. Using thinner blades for the impeller allows a 12% reduction of the hemolysis index in average, while reducing its diameter leads to an index 2.8 folds lower at 0.5 L/min.
Conclusion: The present investigation shows the promising hemocompatibility of our centrifugal pump. Concerns about very high hemolysis generated at low flow rates could be overcome by reducing the impeller diameter. Experimental validations are planned to support our findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11752984 | PMC |
| http://dx.doi.org/10.1111/aor.14899 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.
J Am Coll Cardiol
August 2025
Cardiovascular and Thoracic Department, Città della Salute e della Scienza Hospital, Turin, Italy; Department of Surgical Sciences, University of Turin, Turin, Italy. Electronic address:
Background: A fully magnetically levitated centrifugal-flow pump (HeartMate 3 [HM3]) has significantly reduced thromboembolic events in left ventricular assist device (LVAD) patients, potentially modifying the trade-off of ischemic and bleeding events with current management strategies.
Objectives: The authors sought to characterize the opposing risk of ischemic and bleeding hemocompatibility-related adverse events (HRAEs) in LVAD carriers with contemporary practice.
Methods: We included 4,320 patients undergoing centrifugal-flow LVAD implantation (HeartWare [HVAD] cohort: 2,088, HM3 cohort: 2,232) in EUROMACS (European Registry for Patients with Mechanical Circulatory Support).
A Miniaturized Centrifugal Pump ECMO System Enhances Hemocompatibility in Small Animal Models.
Biotechnol J
August 2025
School of Precision Instrument and Opto-electronics Engineering, Tianjin University, Tianjin, China.
Extracorporeal membrane oxygenation (ECMO) is a fundamental treatment for cardiovascular and severe pulmonary diseases, with small animal models providing critical insights into organ protection during cardiopulmonary bypass and ECMO therapy. Conventional roller pumps, however, induce hemolysis and organ injury through repetitive compression-shear exposure, severely limiting their utility. While centrifugal pumps reduce shear stress and are effective in large animal ECMO, their flow range and priming volume are unsuitable for small animals.
View Article and Find Full Text PDFOptimization of secondary flow path clearance in centrifugal blood pump: a combined numerical and experimental study.
Front Physiol
June 2025
School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Introduction: Blood pumps as mechanical circulatory support (MCS) devices are widely used for patients with ventricular heart failure, and improving blood compatibility remains a key focus for researchers.
Methods: The effects of secondary flow path clearance on the performance and hemocompatibility of a centrifugal blood pump are investigated in this study. A blood pump of the specific design was developed for modeling and computer simulation, and 25 models were generated by varying its internal and outer clearance between 600 and 1,000 μm.
What Are the Best Biocompatible Materials for Extracorporeal Membrane Oxygenation.
J Funct Biomater
June 2025
Methodist Heart and Lung Institute Vascular Center, 4410 Medical Dr Ste 420, San Antonio, TX 78229, USA.
Extracorporeal membrane oxygenation (ECMO) is a crucial life support therapy for patients with severe cardiac and respiratory failure. However, the complications associated with venoarterial ECMO (VA-ECMO), including thrombus formation, bleeding, and hemolysis, remain significant challenges that impact patient outcomes and healthcare costs. These complications primarily arise from blood-material interactions within the ECMO circuit, necessitating the development of biocompatible materials to optimize hemocompatibility.
View Article and Find Full Text PDFComputational and Experimental Assessment of Shear-Induced Blood Trauma by HeartMate II, HeartMate 3, and BrioVAD.
ASAIO J
June 2025
From the Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland.
Although durable mechanical circulatory support (MCS) has been promising in supporting advanced heart failure patients, device hemocompatibility-related complications remain a major concern compared with heart transplantation. We investigated the blood damage potential of the three most recent clinically available, implantable MCS devices and compared their biocompatibility performance. One axial pump (HeartMate II) and two centrifugal pumps (HeartMate 3 and BrioVAD) were chosen for this study.
View Article and Find Full Text PDF